Answers are grounded in this paper and cite their sources.
Efficacy results demonstrated that the groups of HIV-experienced patients receiving the new ARV + OBT were more likely to achieve viral suppression when compared to the control groups. However, most of these trials may be at a high risk of bias. Thus, there is still not enough evidence to stipulate which combinations are the most effective for therapeutic regimens that are to be used sequentially due to documented multi-resistance.
No takes yet. Share an insight, caveat, or question.
Mocellin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: